Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Elli Roberts

Physician Assistant, Medical Shawnee Mission, KS Physician Assistant

NPI 1578953162 CMS profile 10867696

7450 Kessler St Ste 300, Shawnee Mission, KS 66204

Open in the dashboard

General payments

$8,321

442 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elli Roberts of Shawnee Mission, KS is reported in the CMS Open Payments database as having received $8,321 across 442 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,211 54
2024 General $2,232 105
2023 General $2,641 145
2022 General $2,044 125
2021 General $194 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elli Roberts
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Elli Roberts were reported at $1,211. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Elli Roberts Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $194 $156 $41–$563 $132
2022 $2,044 $185 $55–$649 $149
2023 $2,641 $199 $58–$717 $160
2024 $2,232 $206 $62–$740 $164
2025 $1,211 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $1,395 69 payments
  2. Novo Nordisk Inc $1,100 66 payments
  3. Abbott Laboratories $781 64 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $639 30 payments
  5. Corcept Therapeutics $632 31 payments
  6. Radius Health, Inc. $431 18 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $425 25 payments
  8. AstraZeneca Pharmaceuticals LP $298 13 payments
  9. Tandem Diabetes Care, Inc. $283 8 payments
  10. Amneal Pharmaceuticals LLC $280 16 payments
  11. Other $2,057 102 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,321 442 payments
Products named General payments · program years 2021–2025
  1. Ozempic $881 56 payments
  2. RYBELSUS $881 56 payments
  3. JARDIANCE $663 31 payments
  4. Kerendia $639 30 payments
  5. Korlym $632 31 payments
  6. MOUNJARO $570 31 payments
  7. FreeStyle Libre 3 $482 38 payments
  8. Tymlos $431 18 payments
  9. t:slim X2 Insulin Pump with Control-IQ $283 8 payments
  10. UNITHROID $280 16 payments
  11. Other $3,856 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,785

Median for Physician Assistant: 241

Drug cost

$904,722

Median for Physician Assistant: $4,110

Branded share of claims

65.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 222 $292,884
Jardiance Empagliflozin Brand 156 $159,006
Mounjaro Tirzepatide Brand 85 $108,946
Trulicity Dulaglutide Brand 47 $79,401
Tresiba Flextouch U-200 Insulin Degludec Brand 26 $46,545
Farxiga Dapagliflozin Propanediol Brand 28 $32,550
Tresiba Flextouch U-100 Insulin Degludec Brand 38 $27,704
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 121 $19,843
Rybelsus Semaglutide Brand 12 $19,106
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 16 $17,812

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$103,466

Of which drugs: $65,148

Medicare patients

300

Average age 74

Services billed

4,591

195 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 67%
Arthritis 43%
Chronic kidney disease 39%
Osteoporosis 32%
Ischemic heart disease 31%
Depression 22%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 41 3,120 $63,388

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $213
  • Boehringer Ingelheim Pharmaceuticals, Inc. $126
$340 156 —
Tymlos
  • Radius Health, Inc. $187
$187 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $179
$179 12 —
MOUNJARO
  • Lilly USA, LLC $177
$177 85 —
RYBELSUS
  • Novo Nordisk Inc $158
$158 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

442 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record